The effect of chlorpromazine on the net intestinal accumulation of fluid induced by Escherichia coli heat-stable (ST) enterotoxin in an infant mouse model was examined. Chlorpromazine, when administered with ST enterotoxin, caused a highly significant decrease in net intestinal fluid accumulation. The inhibition of ST activity was dose dependent with various concentrations of chlorpromazine (P < 0.001). A significant inhibition of toxic activity was also observed when chlorpromazine was administered before (P < 0.02) or after (P < 0.05) ST (10, 23) and ST (10, 24) enterotoxins are capable of inducing a catastrophic diarrheal illness in human subjects. The LT enterotoxin is biologically and immunologically similar to the enterotoxin produced by Vibrio cholerae. Numerous studies have demonstrated that both cholera enterotoxin (CT) and LT enterotoxin elicit a dose-dependent activation of adenylate cyclase (EC 4.6.1.1.), which converts adenosine 5'-triphosphate to adenosine 3',5'-cyclic monophosphate (cAMP), and hence elevates intracellular cAMP levels (1, 7, 15, 21, 25, 26) . cAMP presumably regulates ion and water transport across the intestinal mucosa by inhibiting coupled sodium and chloride absorption by villus cells and by stimulating secretion of anions from crypt cells (6, 11, 14) . In this regard, Holmgren et al. (11) reported that chlorpromazine reversed CTand LT-induced fluid accumulation in mice. Thus, it has been suggested that chlorpromazine reverses the secretary effect of CT and LT enterotoxins by inhibiting adenylate cyclase activity (11, 17). More recently, Rabbani et al. (22) reported the ability of chlorpromazine to reduce fluid loss in cholera patients.
Two distinct extracellular enterotoxins, heat labile (LT) and heat stable (ST), are elaborated by enterotoxigenic Escherichia coli. Both LT (10, 23) and ST (10, 24) enterotoxins are capable of inducing a catastrophic diarrheal illness in human subjects. The LT enterotoxin is biologically and immunologically similar to the enterotoxin produced by Vibrio cholerae. Numerous studies have demonstrated that both cholera enterotoxin (CT) and LT enterotoxin elicit a dose-dependent activation of adenylate cyclase (EC 4.6.1.1.), which converts adenosine 5'-triphosphate to adenosine 3',5'-cyclic monophosphate (cAMP), and hence elevates intracellular cAMP levels (1, 7, 15, 21, 25, 26) . cAMP presumably regulates ion and water transport across the intestinal mucosa by inhibiting coupled sodium and chloride absorption by villus cells and by stimulating secretion of anions from crypt cells (6, 11, 14) . In this regard, Holmgren et al. (11) reported that chlorpromazine reversed CTand LT-induced fluid accumulation in mice. Thus, it has been suggested that chlorpromazine reverses the secretary effect of CT and LT enterotoxins by inhibiting adenylate cyclase activity (11, 17) . More recently, Rabbani et al. (22) reported the ability of chlorpromazine to reduce fluid loss in cholera patients.
In contrast to CT and LT, ST does not stimulate intracellular cAMP levels, but produces a rapid elevation of intracellular guanosine 3',5'-cyclic monophosphate (cGMP) concentrations (9, 12, 19) . The present study examines the effect of chlorpromazine on net intestinal fluid accumutation induced by E. coli ST enterotoxin in an infant mouse model before, during, and after initiation of the toxic response.
MATERIALS AND METHODS
Microorganism. E. coli PB-122-B1 (serotype 080: H9) was obtained from Doyle Evans (University of Texas Medical School, Houston, Tex.). This strain was originally isolated from a case of traveler's diarrhea in Mexico and has maintained stability of the ST enterotoxin plasmid in the laboratory (5). Stock cultures of the organism were lyophilized in sterile fetal calf serum and stored at -70'C until required.
Toxin production. A lyophilized culture of the microorganism was reconstituted and inoculated onto a Trypticase soy agar slant (Difco Laboratories, Detroit, Mich.). After 18 h of incubation at 370C, the slant was harvested with 1.0 ml of the synthetic medium of Alderete and Robertson (2), and 0.1 ml was used to inoculate a preculture of 50 ml of synthetic medium in a 250-ml Erlenmeyer flask. The preculture was then incubated for 18 h at 370C and used as an inoculum for toxin production. Two-liter Erlenmeyer flasks, each containing 400 ml of synthetic medium (2), were inoculated with 50 ml of the seed culture, resulting in an initial optical density (at 540 nm) of 0.05. The organism was grown for 8 h in a platform shaker (160 rpm) at 370C. The culture was then centrifuged at 16 ,000 x g for 1 h, and the supernatant was filter-sterilized (0.45 tm; Millipore Corp., Bedford, Mass.). The sterile supernatant was partially purified by collecting the filtrate from an Amicon DM-5 ultrafiltration membrane (Amicon Corp., Lexington, Mass.) and dialyzing over an Amicon UM-2 ultrafiltration membrane (nominal molecular weight cut-off = 1,000). The UM-2 retentate was then twice dialyzed with an equal volume (10 ml) of 0.005 M potassium phosphate EFFECT OF CHLORPROMAZINE ON ST ENTEROTOXIN 1001 buffer (pH 7.0), filter sterilized (0.45 num), and assayed for toxic activity in infant mice.
Infant mouse assay. The infant mouse model of Dean et al. (4) was routinely used to assay for toxic activity. Briefly, infant mice (2 to 4 days of age) were randomly separated into groups of four and injected percutaneously into the stomach with a 0.1-ml sample containing 0.02% Niagara Sky Blue. After 3 h of incubation at 230C, each animal was killed by decapitation, and the entire intestinal tract was removed and weighed. The ratio of intestinal to remaining body weight was used as a measure of the amount of toxic activity as described elsewhere (4). If dye was not present in the stomach at death, the animal was discarded.
A dose-response titration curve was constructed as previously reported (18) from dilutions of the concentrated UM-2 retentate. A dilution giving a toxic response in the linear portion of the titration curve was routinely used. In all subsequent drug studies this was referred to as a standard toxin dilution. The standard toxin dilution gave a ratio of approximately 0.100 when mixed with an equal volume of 0.005 M potassium phosphate buffer (PPB) at pH 7.0.
Simultaneous treatment with chlorpromazine.
A (Fig. 1) . In the absence of chlorpromazine, titration of the standard toxin dilution gave a response of 0.101 ± 0.009 (data not shown). This response, in the presence of various concentrations of chlorpromazine, was significantly diminished and dose dependent from 25 to 100 jig of drug. The difference between toxin alone and 50 or 100 ig of chlorpromazine was significant (P < 0.001), whereas drug concentrations of 5 and 10 ,ug showed no significant reduction of fluid accumulation. Furthermore, no significant dif- Both pre-and posttreatment of infant mice with 100 ug of chlorpromazine resulted in the partial inhibition of net intestinal fluid accumulation. When 100 1Lg of chlorpromazine was injected 30 min before administration of the standard toxin dilution, there was a significant (P < 0.02) decrease in fluid accumulation when compared with control groups of mice receiving buffer 30 min before challenge with the standard toxin dilution (Table 1) 25 to 100 jig when the drug was administered simultaneously with toxin. The administration of chlorpromazine 30 min before or 30 min after the initiation of intestinal fluid accumulation resulted in a significant, but modest, inhibition of the toxic response. Mice killed 30 min after toxin challenge showed that a significant amount of fluid had already accumulated before administration of the drug. Giannella and Drake (9) have shown a significant accumulation of intestinal fluid as early as 60 min after challenge with ST enterotoxin. Recent studies, using E. coli or cholera heat-labile enterotoxins (11, 17, 22) , or viable E. coli (16) in other animal systems, have used lower dosages of chlorpromazine. Whether E. coli ST-induced fluid secretion is more resistant to the inhibitory effect(s) of chlorpromazine than E. coli or cholera enterotoxins or viable E. coli is not known. Further studies, using equivalent toxic units, will have to be performed in a comparable animal system to quantitate the effect of chlorpromazine on E. coli enterotoxins, cholera enterotoxin, and viable E. coli.
It has been demonstrated that chlorpromazine has an inhibitory effect on adenylate cyclase (13, 20, 27) . However, Holmgren et al. (11) reported that chlorpromazine inhibits intestinal fluid secretion mediated by dibutyryl-cAMP, a finding which indicates that the primary action of this drug may be targeted at a point subsequent to the stimulation of adenylate cyclase. Since ST enterotoxin mediates intestinal fluid accumulation by a mechanism independent of the stimulation of adenylate cyclase, i.e., the stimulation of guanylate cyclase activity (8) , the present study indicates that the induction of intestinal fluid by heat-labile (CT and LT) and heat-stable (ST) enterotoxins may have a common intermediate which leads to an alteration of mucosal active ion transport. The presence of a common pathway would explain the ability of chlorpromazine to reverse the effect of bacterial enterotoxins that separately modulate cAMP and cGMP concentrations. This observation may be fundamentally important for further studies on the use of chemotherapeutic agents in the treatment of enterotoxigenic diarrheas.
Further investigations may indicate the therapeutic use of chlorpromazine for the treatment of toxin-mediated diarrheas. Chlorpromazine has been used to successfully treat Asiatic cholera (22) . Recent studies by Holmgren et al. (11) have shown that chlorpromazine is a potent inhibitor of cAMP-mediated intestinal secretion.
Results of the present study indicate that chlorpromazine will antagonize the effects of cGMPmediated intestinal secretion both before and after induction of the toxic response. Further, chlorpromazine has a relatively high therapeutic index and flat dose-response curve. These characteristics indicate that it can be used over a wide range of dosages. The drug has the added benefit of controlling nausea 
